רווח למניה בשנים עשר החודשים האחרונים: ImmuCell Corp (ICCC)

ImmuCell Corporation (ICCC) profits are based on wholesale sales of First Defense biologicals to large dairy complexes. The TTM annual earnings per share visualizes this financial flow, where 0.20 expresses the latest level of the metric. Stability is ensured by proprietary antibodies for calves integrated into farm sanitary standards, while current supplies of veterinary products create a real foundation of value.

For ImmuCell Corporation (ICCC), the TTM earnings per share chart reflects the effectiveness of its strategy implementation within the veterinary immunology sector. This indicator represents the total net income over the last four quarters divided by the total number of shares. Such a mechanism smooths out temporary fluctuations, demonstrating the business's actual ability to generate profit. The stability of this metric confirms management's scientific expertise in producing critical livestock products, allowing investors to assess the company's fundamental viability.